bit.bio
bit.bio is an award-winning human synthetic biology company whose mission is to code cells for novel cures. They have developed an end-to-end platform for the creation of any human cell type. With their cutting-edge and patent-protected opti-ox™ precision cell programing technology, bit.bio can deterministically program human induced pluripotent stem cells (iPSCs) into a chosen cell identity with unprecedented biological consistency at an industrial scale and approximately 10 times faster than conventional methods. Their platform has the potential to unlock a new generation of medicines.
Latest Content
App Note / Case Study
Studying the Link Between Cell Migration and Neurodegenerative Disease With iPSC-derived Microglia
In this application note, researchers from Medicines Discovery Catapult (MDC) evaluated the suitability of iPSC-derived microglia as a model for studying the mechanics of microglia activation, shedding light on their role in neurodegeneration and the potential for therapeutic targets.
App Note / Case Study
Improving Physiological Relevance in Neurological Disease Drug Development
This case study explores the use of human iPSC-derived microglial cells as a more reliable model for neurobiological drug development.
Poster
Improving Physiological Relevance in Functional Genomics Screens
This poster describes the use of CRISPR-ready iPSCs, which are engineered to constitutively express Cas9, enabling the rapid generation of high-efficiency gene knockouts and CRISPR screens in a functional, physiologically relevant cell background.
Video
How To Accelerate Research and Drug Discovery in Motor Neuron Disease: A Deep Dive Into Precision Reprogrammed Human iPSC-Derived Motor Neurons
In the Teach Me in 10 video, Dr. Marcos Herrera-Vaquero, bit.bio discusses motor neurons and their critical role in Motor Neuron Diseases (MNDs) such as amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA).
App Note / Case Study
Speeding Up Neuroscience Research
Delve into this case study to explore how a research lab at King’s College London used hiPSC-derived neurons to shed light on synaptic biology and potential treatments for psychiatric conditions.
App Note / Case Study
Advancing ALS Research With iPSC-Derived Disease Models
This app note delves into the role of TDP-43 protein aggregates in the disease's progression. Charles River Laboratories and bit.bio present a breakthrough in ALS research with genetically matched ioGlutamatergic Neurons, providing a crucial in vitro model.
Webinar
Uncovering the Glioma Microenvironment With In Vitro Neuronal Models
On-Demand
In this webinar, you’ll hear from Dr. Brian Gill about his research into neuron–glioma interactions and how they contribute to seizures and tumoral growth.
Online Event
Innovations in Disease Modeling 2024
On-Demand
Explore the tools and techniques being used to study diseases in the lab. Discover how advances in cell culture and disease modeling are supporting diagnostic and therapeutic development.
Industry Insight
The Pathology of Proteins: A Tangled Tale of Alzheimer's
Explore the current understanding from the scientific literature on how protein misfolding, mislocalization and malfunction can lead to Alzheimer's disease.
Video
Revolutionizing In Vitro Disease Models With iPSC Reprogramming Technology
In this Teach Me in 10, we are joined by Dr. Will Bernard to get a primer on the latest innovations in in vitro human cell technology.
Advertisement
